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From institutionalization to vocational independence

Pierre Daniker
1917-1998
Chlorpromazine
1952

July 1992, Clozapine

Progress in Cognition and cognitive neurosciences of schizophrenia

•

Schizophrenia A Brain
Disease

•
•
•

‘Mindless Brain’

•

Cognitive Behavior
Therapy in Schizophrenia

•

Neuroimaging Correlates of
Neuropychological Deficits

‘Brainless Mind’
Cognitive Theories;
theories of Organization

Processing external
stimuli , executive
memory and cognition.

• Why are we talking so much about
Cognition now a days.

•

85% prevalence of cognitive symptoms, while
Delusions and hallucinations are seen in only 40%

•
•

Fact that these are fairly stable, &
Correlation to Outcome

Cognition as an outcome measure in schizophrenia
Kraepelin : adopted the term
dementia praecox for a
condition characterized by
early psychosis and cognitive
deterioration
Bluer though
emphasized on
disconnection between
affect, thought and
perception, still viewed
cognitive deficit as
integral to disorder

The perceived importance of
Cognition in schizophrenia has
since waxed and waned

Kraepelin’s Cognitive and
negative symptoms were
overshadowed by positive
symptoms
RDC DSM iii & iv all
emphasized on PS and
Cognition is still not
included in criteria

A renewed interest in cognition was seen recently, spurred by
strong empirical relationship between cognition and real world
functioning

Outcome Status

•

10% of all patients with schizophrenia work full
time

•
•
•

Only 1/3 ever work part time
Fewer than 10% of male patients have a child
Self care deficit is reflected in high rates of medical
morbidity

Research in schizophrenia is at a stage where in it has been irrefutably demonstrated
by a host of workers that the
key factor for social deficit, impairment, dysfunction and disability in
schizophrenia is the problem particularly associated with cognitive set and
consequences of neurodvelopmental process.
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Functional Outcome Since 1895
50.0

Mean Percentage Improved at Follow- up

37.5
25.0
12.5
0
1895 1905 1915 1925 1935 1945 1955 1965 1975 1985
Am. J.Psychiatry; Hegardty JD, et al . 1994

•

‘Several studies have failed to demonstrate positive correlation
between positive symptoms and functioning’

•

Change In QLS Total Score With Change in Memory Function Positive Linear Correlation; Buchanan RW et al Biol.Psychiatry
1994;36

Impaired Cognition as a Core feature of
schizophrenia and Cognitive symptoms lack
Correlation with Positive symptoms and severity,
suggesting its independence

•

Individual reports that cognitive decline exists in
schizophrenia started appearing early 1980; first
was in 1977 by Cohen et al

•

The largest meta analysis for schizophrenia till date
by Heinrichs and zakzanis 1998 established a
performance lower by 0.46 to 1.46 SD

•

Explanation --- non disease factor, EPS,
Medication etc.

•

All these were done on chronic patients , severely
de-compensated, institutionalized... reports were
not taken seriously.

IS there a deficit, if so how much?
Magnitude of Cognitive Deficits in Schizophrenia
Meta-Analysis; 204 studies, 7420 patients and 5865 controls
Dig Span
Vocab
Block Des
WCST

SD Units
Trails B

Characteristic profile in
schizophrenia: maximal impairment
in memory, attention, and executive
function; relative preservation of old
learning and visual perceptual skills.

CPT
Fluency
Vis Mem
Verb Mem
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-1.0

-0.5

Heinrichs & Zakzanis
Neuropsychology 1998

0.0

Healthy Comparison Mean

Large number of studies consistently indicated benefit of Cognitive enhancement to
outcome and continue to raise our expectation

1994-Saykin et al, Philadelphia, Archives - the first
reliable report for neuropsychological deficit in
neuroleptic naive first episode patients
1996 Meltzer wrote about ‘cognition schizophrenia and
atypical antipsychotics’
By 1998 a correlation was established by imaging
studies between cognitive decline, N-P Dysfunction,
behavioral measures and neuroanatomical changes
by 2000/2001 concept of cognitive dysfunction and its
contents was fairly established and various thought
disorders seen in schizophrenia were explained by this
theory like: cognitive neuropsychiatric model of
persecutory delusions by Backwood et al 2001 AJP

Prevalence: how many patients show this
deficit
left side shift by 20%

30.0

Schizophrenia
Normal control

22.5
15.0
7.5
0
50-55

51-60

61-70

71-80

81-90 91-100 101-110 111-120 121-130131-140141-150

Distribution of Total Score on Repeatable Battery for Assessment
of N-P status Randolph et al : Shift by 2 SD

Where is the lesion and what is the deficiency

•

2002 hippocampal deformities in schizophrenia
characterized by high dimensional brain mapping
AJP Csernansky et al

•

2003 Neuronal correlates of episodic encoding and
recognition of words in unmedicated patients
during acute episode . Hofer et al, AJP

•

2003 Diagnostic specificity and neuroanatomical
validity of neurological abnormality in first episode
psychosis

•

Memory and executive function

The course of schizophrenia
Episodic, w/o interepisode
deficits

Episodic, w/interepisode
deficits ( common)

Broad therapeutic window for
Prevention/Early intervention

•

Chronic, deteriorating

It has been further demonstrated that this cognitive change (dys-function
or deficit) is the one which settles not only in early course of
pathogenesis in adolescence and early adulthood, but may have
originated during the prodromal phase of the illness in the individuals
who are at-risk.

•

•

Impaired Cognition is not an epiphenomenon of clinical
symptoms.

•

Some studies have reported normal cognition in a
significant number of people.

•

80-90% of twins with schizophrenia scored below their
unaffected twins on N-P tests.

•

98% of people with schizophrenia performed below the
level predicted by estimates of their premorbid functioning

Several Studies have now demonstrated that Cognitive
deficits occur in first episode of schizophrenia patients
who have never taken antipsychotics.

Unlike Schneider’s first rank Symptoms
Cognitive symptoms Correlate highly with
measures of functional outcome
Overwhelming evidence of cognitive deficit has spurred
USA NIMH to target such deficits by pharmacological
interventions (MATRICS)
Separate domain of deficit Vs generalized deficit
This debate has implication for etiology:
Whether the underlying brain abnormalities are
local or global?

Effect Sizes

Antipsychotics and Cognitive
Enhancement

0.500

Conventional
APD
Diminish
Cognition

0.375
0.250
0.125
0
Global cognitive index

clozapine
Olanzapine
Risperidone
Quetiapine
All AAPD Combined

Latest Data:
gain from atypical
are marginal. For Schizophrenia
enhancement
we need to look
somewhere else
Atypical brought
the euphoria of
enhancement

A meta-analysis of 46 recent studies for N-P Change to clozapine,
olanzapine, quetiapine, and Risperidone in schizophrenia;
Woodward et al, Int J Neuropsychopharm.2005

Conventional APD
Do not enhance
cognition

Progress in NeuroCognition

1985, Historical Clozapine Studies started bringing
in the concept ‘reversibility’ of Cognition by
H.Y.Meltzer et all and other groups.

•

2006 DB study of
combination of
clozapine with
risperidone....:
effects on
cognition...J Cl.
Psychiatry, Dec.
2006

•

CONCLUSION: Adjunctive
treatment with risperidone for
6 weeks in patients with
schizophrenia who had
received chronic treatment
with clozapine does not
significantly improve
cognitive function.
17

Predictive Validity
Cognitive predictors of change
in employment at 12 Month clozapine study

Cognitive status and employment in
schizophrenia
California Verbal Learning Test

CVLT
Remains Unemployed
None to Employed

50.0

*p<.05,**p<.01,***p<.001

Long Delay - Free Recall (mean+_ SD
10.0

37.5

7.5

25.0

5.0

12.5

2.5

0
**CWAT **CIGT ***ACTT
Schizophre Bullatin 1999

Full Time
Part Time
Unemployed

0
Full Time
Part Time
Unemployed
McGurk SR, Meltzer HY.Schizophrenia Res.
2000;45:174-184

Cognitive Change and Symptom Correlations

•
•
•
•
•
•
•

Symptoms e.g. thought disorder* & insight*
Only negative symptoms***
Global symptoms
Duration of untreated psychosis***
Severity dimension
Chronicity dimension
Demography

Correlations were established by sophisticated imaging, observing: neuronal loss, recovery,
anatomical positions and functional pathways,
establishing direct link between ‘brain-lesions’ and functional outcome, providing valid
arguments to look into the brain more and more by pharmacological probes

Some doubts were also raised.

Symptoms & Cognition as
predictors of Community
Functioning
Symptoms after optimal treatment are better predictors
as compared to Symptoms during acute episode
Symptoms ( disorganisation < psychomotor < < reality
distortion ) were more predictive than neurocognition

Ross Norman,Ashok Malla, AJP ,1999

Cognitive deficit and
functional outcome
Effect Sizes (Cohen’s r) Strength of Relationship
Results from four different Mata-analysis

Better work performance

Pooled Estimate Effect Size r*

0.700

Green MF et al , Schizophrenia Bull. 2000;26
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•

Significant
improvement in
cognitive function
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•

Cognitive Enhancement

•

•

Cognitive enhancement
at different illness
phases
6 weeks

0.900

J Cl. Psychiatry. 2006 OCT.

6 months

Normatively derived
Effect Size units

Comparison of Conventional and
atypical antipsychotics effect on
cognition- three different trials

Conventional

Atypical

Global Change
in Effect Size

0.4
0.3

0.675

0.2
0.450
0.1
0.225

0

0

-0.1
Olanzapine

Ziprasidone

Cognitive enhancement at different
illness phases

Keefe

Harvey

First Episode

Bilder
Refractory

Three different trials

• The Evidence of Reversibility
Olanzapine better than Haloperidol
DB trial in the treatment of primary negative
symptom and neurocognitive deficits in schizophrenia
- JCP , J.P.Lindenmayer, 2007, March

•

•
•

Neuropsychological results:
significant differences in
change from baseline to end
point for the olanzapinetreated group were seen for

P-value for Difference between treatments
Global Cognitive Index
Declarative VLM

A} declarative verbal learning
memory ( F= 11.499, df=1,14;
p= 0.021 ) &
B} Motor functioning
domain ( F= 4.405, df=1,31;
p= .044).

Attention Speed
Executive functioning

Simple Motor Functioning

0

0.1

0.2

0.3

0.4

The First Episode:
the paradox and the new hope

• 90% of FEP experience remission at the end
of one year of treatment

• At 5 years follow up 80% had a job
• 80% had a relapse, of that 80% most had
second relapse

• Predictors of outcome do not correlate with
psychotic/remitted status

Recent Studies

•

RSP V QP, NS 6,12 wk EUrAch.Psych l Ns, July
07 QP better Reidel

•
•
•
•
•
•
•

OLN v QP Acute 4, 8 wk JCP july 07 QP better
Keefe Study July 07 OLN.RSP.QP
CATIE
OLn V. HP, Lindermayer JCP march 07 OL better
CLP+RSP Meltzer , No benefit JCP dec 2006
QP v RSP Harvey 8 Wks AJP nov 06, both good
ZP v OLN Harvey 2003

Strategies
1.Cognitive Enhancement
2. Cognitive Preservation

•

Attempts were started to deal early and earliest and
address more investigation.

•
•

‘Early Intervention and Prevention of Schizophrenia’

•
•

CBT, Cognitive Remediation Therapy

Non-pharmacological and Pharmacological methods
were employed to enhance cognition

Several molecules

Cognitive re-mediation therapy (CRT) for young early onset
patients with schizophrenia: an exploratory randomized
controlled trial................Schizophrenia Research August 2007

The Ultra High Risk Individuals
The course of neurocognition and social
functioning in individuals at ultra high risk for
psychosis
Schizophrenia Bulletin August 2007

•

UHR subjects showed significant cognitive deficits at baseline and 2 distinct
profiles of cognitive change over time.

•

On average, 50% demonstrated improvement in social and role functioning
over the follow-up period, while the other half showed either stability or
decline in functioning.

•

Functional improvement was associated with improved processing speed
and visual memory, as well as improvement in clinical symptoms over the
follow-up period.

•

In contrast, patients who did not improve functionally showed stable clinical
symptoms and cognitive performance over time.

Drugs- tried, tested, failed, & survived
to improve- cognition-outcome-depression-NS,
complex.
Every thing under the SUN

•
•
•
•
•
•

Poly pharmacy
Many antipsychotics
Antidepressant
Mood stabilizers
Conventional and
atypical
Psychotherapy

•
•
•
•
•
•

Dopamine antagonists
Dopamine agonists
Serotonine blockers
Alpha-adrenergics
Cholinesterase inhibitors
Herbal medicines

•

Effect of donapezil added to atypical antipsychotics
on Cognition in schizophrenia......World J. Biol.
Psychiatry
Conclusions: Adjunctive treatment with donepezil improves cognition in
patients with schizophrenia who are stabilized on atypical antipsychotics

•

Despite the beneficial effects of atypical antipsychotics on cognition, many
schizophrenic patients continue to suffer

•

Postmortem findings suggest that altered cholinergic activity is involved in
cognitive impairment in schizophrenia.

Experience with Adjunctive
Rivastigmine and AAPD on Cognitive
deficits - negative results

?

It was proposed that cognitive impairment: is
a separate domain

• Cognitive symptoms correlate poorly with
positive symptoms

• Cognitive symptoms are enduring whereas
positive symptoms are phasic

• Improvement in cognition is independent of
improvement in positive and negative
symptoms and EPS in most but not all
studies

Pharmacological and Non-pharmacological measures

cognition
Sequential
Improvement

x

outcome

• APD
• Cognition
• Functional outcome
• Social & Vocational outcome

Model Building:

Neurocognition, Interventions, Mediators, and
Functional Outcome
Promising
Mediating
Variables

Interventions
Psychopharmacological

Other
Factors
Clinical
Symptoms

Learning
Potential

Functional
Outcome
Domains

• Social
• Occupational

Neurocognitive
Capacities

• Independent
Living
Social
Cognition

Psychosocial

Volition
Environmental

Green, Meltzer, Newcomer & Bellack, APA 2000

• Rehabilitation
Success

Tools for measuring cognition: Depends upon the
research questions
1.Neuropsych.Batteries, manual or Computerized
2.Psycho-physiological Tests

•
•
•
•
•
•

Validity
Time required
Domain speficity
Correlation with fuctional
outcomes
Statistical convertibility
Culture neutrality
33

•
•
•
•
•

CATIE battery

•

UPSA, MCCB

MATRICS battery
BCA
BACS
RBANS,WAIRIII,WMS,VCST

•
Highly
Complex
statistical
methods
have been
developed.
Results are
being
analysed
and reanalysed,
as never
before

CATIE ...Study Highlights

• The study was completed at 57 US centers. 18-65,
Schizophrenia
• Randomized to receive olanzapine, quetiapine,
risperidone, ziprasidone, or perphenazine. Dosing flexible and based on clinicians' judgment.
Participants and assesors were blind.
• Neurocognitive testing was performed using 11
different tests. Testing was completed at baseline and
then at 2, 6, and 18 months of study treatment
The primary study outcome was the change in cognition
from baseline to 2 months in each treatment group

•

Current status - CATIE Trial
2 Months, N=467 without TD

•
•

Improvement from base

•

Perphenazine as good as
other atypical.

0.300

•

When group with TD
added, improvements
sustained

0.225

No significant inter-group
differences

•

Patients with TD had less
over all improvement

•

Ziprasidone showed less
improvement when TD
group was excluded

Olanzapine, p<.002
Perphenazine, p<.001
Quetiapine, p<.001
Risperidone, p<.001
Ziprasidone,p<.001

0.150
0.075
0
LSM Improvement in Neurocognition

• Current status-CATIE Trial, 2 Months,

individual NC domains across treatments
• No significant disparity between the groups in improvement across the
individual NC domains
•

Change in the individual measures were small but consistently positive

Olanzapine
Perphenazine
Quetiapine
Rsperidone
Ziprasidone (Data set 3)

0.4
0.3
0.2
0.1
0
-0.1
Speed

Reasoning

Working Memory Verbal Memory

Vigilance

• Current status, CATIE Trial , at 6 Months,
N= 523

• The NC composite score improved

(p <0.001) for each of the treatment groups
from base to 6 months

• There was no difference between the

groups on the change in the NC
composite score (p=0.35), or any of the
NC domains (all p values < 0.01)

• Current status - CATIE Trial, at 18 Months,
N=303

•

37% patients were from 2
months analysis

•
•

21% of original pool

•

•
•

Sample was found
representative of entire pool on
NC domains,
the improvement in composite
score from month 2 to month 18
was 0.11, suggesting that most
of the cognitive improvement
occurred in first 2 months of
treatment
Perphenazine group had better
improvement than Olanzapine
group or Risperidone group
Ziprasidone and Quetiapine

Olanzapine, p<.002
Perphenazine, p<.001
Quetiapine, p<.001
Risperidone, p<.001
Ziprasidone,p<.001
0.500
0.375
0.250
0.125
0
LSM Improvement in neurocognition

The relationships between change in cognition and
change in social and vocational outcome??

• Current status: Keefe Study, AJP 2007 July
•
•

•

Olanzapine
Risperidone
Unaffected siblings show
premorbid cognitive decline
The team concludes: “To our knowledge,
this is the first study demonstrating that
unaffected siblings of people with familial
schizophrenia have poor academic
functioning during adolescence and
deterioration in academic performance
between childhood and adolescence
compared with controls.
Familial liability to schizophrenia and
premorbid adjustment British J Psychiatry
2007; 191: 260–261

Quetiapine

0.4
0.3
0.2
0.1
0
Week 12

Week 52

There were small differences
between groups
•

Pooled across treatments, the partial correlations (controlling for baseline cognition and
clinical symptoms) were small (0.14 and 0.18, respectively) at 12 weeks and roughly
medium (0.22 and 0.36, respectively) at 52 weeks

•

Associations are relatively small -- for two reasons

Olanzapine,WK12
Quetiapine,WK12
Risperidone,WK 12

0

-0.125
-0.250
-0.375

CGI, Severity items PANSS-PS

PANSS-NS

PANSS-GP

PANSS-Total

Enhancement basically occurs at
2 months and sustains at 52 months
•
•

One is that we do not have a clear pre-cognitive treatment effect in this study.
Second, there is no psychosocial treatment component as part of this design that would facilitate translation
of any cognitive benefits to the level of community functioning

Week 52

0
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-0.525

al

P

To
t
SS
N

Quetiapine
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Olanzapine
Risperidone
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N
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-0.700

Quetiapine’s superiority at week 12 also is not very robust and it does not
sustain up to week 52 .
The discussion and explaination is lacking on this point.
• The explanation for superiority of quetiapine based upon blocking of
muscarinic receptor by quetiapine is insufficient as there is a complex
biological process for cognition.
0.60

12 Weeks

0.45

olanzapine
Risperidone

Quetiapine

52 weeks

0.30
0.15
0
Vocational
Correlation pearson r
CATIE Score and
Functional outcome

Social

Vocational
Heinrichs-Carpenter QOL Scale

Social

Conclusion - that we should not plan to address our
unmet need for cognition enhancement with
antipsychotic medications

•

The improvements seen with the second-generation
medications are within the range of expectation.
For this reason,

•

It is not known whether all three drugs have
modest beneficial effects on cognition or whether
they are all cognitively neutral

•

The cognitive effects - 52 weeks were not
significant, because of a slight reduction in effect
size and reduced statistical power from attrition.

•

We need to look elsewhere

Cognition, Drug Treatment, and Functional
Outcome in Schizophrenia: A Tale of Two
Transitions
Michael F Green. The American Journal of
Psychiatry. Washington:Jul 2007. Vol. 164, Issue.

•

Optimism that second-generation antipsychotics
would yield cognitive improvements has
progressively been tempered as treatment effect
sizes have progressively dwindled, possibly as a
result of dosing factors (as doses of comparators
became lower) or patient selection factors (as more
patients received second-generation medications)

How to Explain cognitive enhancement by atypicals
2. Atypical neuroleptics stimulate neurogenesis
in adult rat brain
Wakade & Mahadik . Journal Neuroscience Res.

•

1.Unlike conventional 50.0
antipsychotics
atypicals have been
37.5
shown to be
neuroprotective i.e.,

atypicals can prevent brain 25.0
tissue loss associated with
psychosis and stimulate
12.5
neurite extension,
neurogenesis, and cell
0
survival

3. Nerve growth factor (NGF) in
Plasma schizophrenia subjects;
Schizophrenia Bull. 2003

**
**

*

Normal NGF (pg/ml)
Never medicated FEP patients
Chronic patietents treated with typicals
Chronic patients treated with aypicals

Functional neuro-anatomy of cognitive deficits
in schizophrenia - temporal lobe model
Studies of Cognitive activation and fMRI Studies of working
memory and cognitive controls Reveal

• Temporal Sagital Gyres (TSG)
• Dorsolateral Pre-frontal Cortex
• Hippocampal Formation (LTM)
• Corpus Callosum

DLPFC

New treatments for cognition in
schizophrenia

•
•
•
•
•
•
•
•

Muscarnic antagonist: N-desmethyl clozapine
Glutamate enhancers: Org 24448, LY 451 395
GABA-A partial agonist: NGD 97-1
Histamine antagonist : BF2-649
Adrenergic modulators : c105
5-HT-1A antagonists : AV 965
Nicotine partial agonist : Tc -1734
Nk-3 antagonist : Sr 42801

The concept of neuronal plasticity and
conditioning for memory

The Nobel Prize in
Physiology or
Medicine 2000
Arvid Carlsson, Paul
Greengard and Eric
Kandel
for their discoveries
concerning
"signal transduction
in the nervous
system"

The COMT Gene
•

Future Direction, New Molecules or New Genes??
COMT val108/158met genotype, cognitive function, and cognitive improvement with
clozapine in schizophrenia...Schizophrenia Research, 2007 Feb

The path from here to there…

cognition
The Wisconsin Card Sorting Task

psychiatric illness

temperament

Genes:

Cells:

Systems:

Behavior:

multiple
susceptibility
alleles each of
small effect

subtle
molecular
abnormalities

abnormal
information
processing

complex functional
interactions and
emergent
phenomena

CONCLUSION:

•
•
•

Cognition is integral to schizophrenia

•

Measurement batteries would be simple and
reliable

•

Amongst various enhancing measures newer
pharmacological molecules are expected

•

Hope that practice of such therapy would be simple
and cost-effective

•

Hope that this would make a difference to life of
patients

A criteria in DSM/ICD expected
Deficits are related to global & social functioning,
and can enhance outcome
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